Streetbeat News

Analyst Ratings

WEN

Stephens & Co. analyst Jim Salera has reiterated an Equal-Weight rating for Wendy's (NASDAQ:WEN) and maintained a price target of $19.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:38 am

PDEX

Ascendiant Capital's analyst Edward Woo maintains a Buy rating on Pro-Dex (NASDAQ:PDEX) and raises the price target from $28 to $30.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:32 am

CWAN

Piper Sandler analyst Arvind Ramnani has maintained a Neutral rating on Clearwater Analytics Holdings (NYSE:CWAN) with a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:12 am

BTCUSD

Crypto analyst Michaël van de Poppe dismisses fears of a major Bitcoin crash, viewing the recent 26% price correction as normal. He anticipates a bull run for Bitcoin until 2026, despite current market downturns and economic concerns.

Portfolio Pulse from Aniket Verma

September 09, 2024 | 8:35 am

ASO

Academy Sports and Outdoors, Inc. (NYSE:ASO) is set to release its Q2 earnings on Sept. 10, with expected earnings of $2.03 per share and revenue of $1.57 billion. Analysts have mixed ratings, with some maintaining 'Outperform' and others downgrading their ratings. The company declared a quarterly dividend of 11 cents per share.

Portfolio Pulse from Avi Kapoor

September 09, 2024 | 7:41 am

PLTR

Palantir Technologies (NASDAQ:PLTR) will be added to the S&P 500 Index, marking a significant milestone for the company. Analyst Daniel Ives from Wedbush views this as a validation of Palantir's growth and profitability potential, driven by its AI platform and U.S. Commercial business. The inclusion is expected to boost Palantir's momentum, especially in the federal sector, and marks the start of a multi-year growth cycle. Wedbush has an Outperform rating and a $38 price target for Palantir.

Portfolio Pulse from Shanthi Rexaline

September 09, 2024 | 6:23 am

GLOB

Globant (NYSE:GLOB) has been analyzed by 15 analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target has increased by 4.41% to $222.07. Analysts have adjusted their ratings and price targets, reflecting a generally positive outlook. Globant's financial performance is strong, with notable revenue growth and net margin, though its ROE is below industry averages.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 9:00 pm

PATH

In the past three months, 11 analysts have rated UiPath (NYSE:PATH), with all ratings being indifferent. The average 12-month price target is $15.36, up from $14.80. Analysts have adjusted their ratings and price targets, reflecting mixed sentiments. UiPath's financials show strong revenue growth but challenges in profitability and returns.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 9:00 pm

TVTX

Analysts have recently updated their ratings for Travere Therapeutics (NASDAQ:TVTX), with a majority showing bullish sentiment. The average 12-month price target has increased by 16.7% to $18.38. Travere Therapeutics has shown significant revenue growth but faces challenges with high debt and low returns on equity and assets.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 9:00 pm

G

In the past three months, five analysts have rated Genpact (NYSE:G), with a mix of bullish and indifferent sentiments. The average 12-month price target has increased by 6.28% to $40.6. Analysts have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Genpact shows strong financial health with impressive revenue growth, net margin, ROE, and ROA, and a favorable debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 06, 2024 | 9:00 pm